REGISTERED NUMBER: 16134861 (England and Wales)

Unaudited Financial Statements

for the Period 13 December 2024 to 31 March 2026

for

NUCLEARMEDIX LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

Professor E O Aboagye

Dr R Fu

REGISTERED OFFICE:

3rd Floor 9 St. Clare Street

London

EC3N 1LQ

REGISTERED NUMBER:

16134861 (England and Wales)

ACCOUNTANTS:

Wilson & Co

Chartered Certified Accountants

3rd Floor

9 St. Clare Street

London

EC3N 1LQ

FIXED ASSETS

Intangible assets

4

70,714

CURRENT ASSETS

Debtors

5

5,709

Cash at bank

669

6,378

CREDITORS

Amounts falling due within one year

6

51,132

NET CURRENT LIABILITIES

(44,754

)

TOTAL ASSETS LESS CURRENT LIABILITIES

25,960

CREDITORS

Amounts falling due after more than one year

7

66,000

NET LIABILITIES

(40,040

)

CAPITAL AND RESERVES

Called up share capital

1

Retained earnings

(40,041

)

(40,040

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 September 2026 and were signed on its behalf by:

Dr R Fu - Director

1.	STATUTORY INFORMATION

NUCLEARMEDIX LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of seven years.

Financial instruments

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference

shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

At the end of each reporting period shares are assessed for impairment. If an item of share is impaired, the

identified share is reduced to its selling price less costs to complete and sell and an impairment charge is

recognised in the profit and loss account. Where a reversal of the impairment is recognised the impairment

charge is reversed, up to the original impairment loss, and is recognised as a credit in the profit and loss account.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 .

4.	INTANGIBLE FIXED ASSETS

Other

intangible

assets

£

COST

Additions

82,500

At 31 March 2026

82,500

AMORTISATION

Charge for period

11,786

At 31 March 2026

11,786

NET BOOK VALUE

At 31 March 2026

70,714

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Other debtors

5,709

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Taxation and social security

1,901

Other creditors

49,231

51,132

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

£

Other creditors

66,000

8.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the period ended 31 March 2026:

£

Dr R Fu

Balance outstanding at start of period

-

Amounts advanced

(22,043

)

Amounts repaid

-

Amounts written off

-

Amounts waived

-

Balance outstanding at end of period

(22,043

)

Professor E O Aboagye

Balance outstanding at start of period

-

Amounts advanced

(4,744

)

Amounts repaid

-

Amounts written off

-

Amounts waived

-

Balance outstanding at end of period

(4,744

)

9.	POST BALANCE SHEET EVENTS

On 10 June 2026, the Company subdivided each ordinary share and each T Ordinary share into 100 shares. As a result, the number of issued ordinary shares increased from 95,000 to 9,500,000 and the number of issued T Ordinary shares increased from 5,000 to 500,000. The nominal value of each share was reduced from £0.00001 to £0.0000001. The subdivision did not result in any change to the total nominal value of the Company's issued share capital.

On 24 July 2026, the Company issued 560,000 ordinary shares with a nominal value of £0.0000001 per share for an aggregate subscription consideration of £100,000.